Strategies for Improving Enrollment of Diverse Populations with a Focus on Lipid-Lowering Clinical Trials.
Oluwabunmi OgungbeJelani K GrantAdeoluwa Segilola AyoolaEyram BansahHailey N MillerTimothy B PlantePayam SheikhattariYvonne Commodore-MensahRuth-Alma N Turkson-OcranStephen P JuraschekSeth S MartinMichael LinCheryl R HimmelfarbErin Donelly MichosPublished in: Current cardiology reports (2023)
Barriers to participation in trials occur at the study, participant, health system, sponsor, and policy level, requiring a multilevel approach to effectively increase participation of under-represented groups in research. Increasing the representation of marginalized and under-represented groups in leadership positions in clinical trials can ensure that their perspectives and experiences are considered. Trial design should prioritize patient- and community-indicated needs. Women and individuals from racially/ethnically diverse populations remain under-represented in lipid-lowering and other cardiovascular clinical trials relative to their disease burden in the population. This limits the generalizability of trial results to the broader population in clinical practice. Collaboration between community stakeholders, researchers, and community members can facilitate shared learning about trials and build trust.
Keyphrases
- clinical trial
- mental health
- phase ii
- phase iii
- healthcare
- study protocol
- clinical practice
- open label
- physical activity
- double blind
- public health
- type diabetes
- case report
- randomized controlled trial
- polycystic ovary syndrome
- risk factors
- metabolic syndrome
- pregnant women
- skeletal muscle
- social media
- genetic diversity
- health information
- pregnancy outcomes
- insulin resistance
- cervical cancer screening